Key Highlights

  • Net loss for the third quarter was USD 1.39 million, down 33% from USD 2.08 million a year earlier, on Revenue of zero in both periods.
  • Operating expenses fell 37% to USD 1.24 million from USD 1.96 million, which the company attributed to lower stock-based compensation and advisory service fees.
  • Working capital was a Deficit of USD 5.79 million at September 30, 2026, with current Assets of USD 1.40 million against current liabilities of USD 7.19 million.
  • On October 30, 2026 the company sold convertible notes with USD 4.11 million of principal for USD 3.39 million of proceeds, netting USD 2.22 million after expenses and a repayment to Lind.

Smaller Loss, Still No Revenue

ABVC BioPharma (NASDAQ:ABVC) filed its Quarterly Report for the period ended September 30, 2026 on November 10, 2026. The company reported a net loss of USD 1.39 million, an improvement of USD 0.69 million from the prior-year quarter, which is shown as restated. Revenue was zero in both periods, so the narrower loss came entirely from lower costs. Operating expenses were USD 1.24 million. Other expense was USD 0.15 million, linked mainly to a Lind settlement expense, and net interest was an expense of USD 0.04 million against income of USD 0.02 million a year earlier. For the nine months, net loss was USD 3.89 million against USD 5.36 million.

Going Concern Warning and a Thin Balance Sheet

The filing states that net cash used in Operating Activities was USD 1.58 million for the nine months, and that these conditions, together with the Working Capital deficit, raise substantial doubt about the company's ability to continue as a going concern. Management listed possible remedies including collecting amounts due under licensing and collaboration agreements, raising capital, cutting expenses and reducing debt. The October 30 note sale helps near-term liquidity, but principal rises by 5% if the Maturity of June 30, 2027 is extended once, and the notes are due within the next year. The 10-Q also says disclosure controls were not effective because of a material weakness that led to a restatement.

Pipeline, BioKey Distribution and Trials Ahead

ABVC is a clinical-stage drug and device developer whose candidates are derived from plants. Its pipeline includes ABV-1504 for major depressive disorder, where a Phase II study is complete, ABV-1505 for adult ADHD, and the Vitargus eye-surgery device, with a Phase II study underway. Two more trials, ABV-1519 for non-small cell lung cancer and ABV-1703 for pancreatic cancer, are expected to begin in the fourth quarter of 2026. After a distribution completed on August 21, 2026, the company kept about 85% of BioKey Cayman, which is now a separate reporting company. The extract gave no revenue guidance, no per-share loss figure and no analyst estimates for comparison.

Where Things Stand

Cost control is working, but survival is still the question. ABVC BioPharma (NASDAQ:ABVC) narrowed its quarterly loss by 33% with no revenue, yet its filing itself says substantial doubt exists about continuing as a going concern. The USD 5.79 million working capital deficit is partly offset by the October note proceeds of USD 2.22 million after expenses. Watch the fourth-quarter trial starts, any further financing, repayment of the convertible notes and whether the material weakness in controls is remediated.